Reviews/GLP-1 Receptor Agonists/Improve polycystic ovary syndrome fertility
Novel · GLP1-NOV-02 · v2
Across five small human studies, women with PCOS and obesity who took a GLP-1 drug tended to ovulate more and become pregnant more often than those who did not. In the largest trial, 35% of women on semaglutide plus metformin later conceived naturally versus 15% on metformin alone [9], and other studies pointed the same way for ovulation [8],[14] and pregnancy [2],[19]. The results all lean in the claim's favour, which is why the panel did not dismiss it. But every study is small, most gave metformin to everyone, and the designs are mixed, so it is hard to say how much the GLP-1 drug itself did versus the weight loss it caused. One study measured pregnancy only after IVF rather than natural conception [2], and in the largest trial the pregnancies happened after the GLP-1 drug had been stopped [9]. That combination of a consistent signal and thin, confounded evidence is why the panel treated the claim as supported but not settled.
Five human primary studies bear on the claim and all point in the same direction. For natural pregnancy, one RCT reported 35% versus 15% for semaglutide-plus-metformin versus metformin [9], one retrospective study found a greater natural pregnancy ratio with liraglutide versus metformin [14], and one single-arm pilot reported 60% of patients achieving pregnancy on semaglutide-plus-metformin [19]. For ovulation, an RCT reported improved ovulation with a GLP-1RA-plus-metformin regimen [8] and the retrospective study reported a greater normal ovulation rate [14]. A separate RCT showed higher IVF pregnancy rates per embryo transfer, 85.7% versus 28.6% (P=0.03), with liraglutide added to metformin [2]. All samples are small (N=20 to N=100) and metformin is given in every comparison, so the GLP-1-specific effect is never isolated. The contested point: The direction of effect is not in dispute, but its attribution is: because metformin is co-administered or used as the comparator in every study, the panel divides on whether the benefit is a GLP-1-specific reproductive action or a downstream consequence of weight loss. The natural-pregnancy leg in particular rests on one RCT whose pregnancies occurred after the GLP-1 drug was stopped [9], one retrospective study [14], and one uncontrolled pilot [19], with the remaining pregnancy evidence coming from an IVF rather than natural-conception endpoint [2].
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Every human study co-administers metformin or uses it as the comparator; no GLP-1RA monotherapy vs placebo exists, so the GLP-1-specific contribution to ovulation and pregnancy is never cleanly isolated.
In [9] the natural pregnancies occurred in weeks 16-40 when BOTH arms received metformin monotherapy, so the pregnancy-rate difference reflects prior semaglutide exposure/weight loss rather than GLP-1 action at conception — indirect support for the claim as worded.
Where it remains uncertain. Every comparison includes metformin and in the largest trial the pregnancies occurred during a metformin-only follow-up phase [9], so the benefit may reflect weight loss rather than a direct GLP-1 reproductive action; one supporting study measured IVF rather than natural pregnancy [2].
Aleatory
Samples run N=20 to N=100 ([19],[14],[2],[8],[9]); with so few participants, ovulation and pregnancy counts are highly sensitive to chance and a handful of events.
Epistemic
No study tests a GLP-1RA alone against placebo; metformin is present in every arm or comparator, so the GLP-1-specific effect is unknown.
Inferential
The benefit may be mediated by weight loss rather than a direct GLP-1 reproductive mechanism; [2] notes comparable weight loss in both arms yet higher pregnancy, but this is not resolved across studies.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Randomised evidence for higher pregnancy rates with liraglutide+metformin, but the primary endpoint is IVF pregnancy rather than natural conception.
“The PR per ET was significantly higher in the COMBI (85.7%) compared with the MET (28.6%) group ( P = 0.03). The cumulative PR in the time frame of 12 months was 69.2% in the COMBI group compared to 35.7% in the MET group.”
Panel auditInternal validity: low · scope of inference: Infertile obese PCOS women undergoing assisted reproduction, liraglutide added to metformin preconception.Key limitations: pilot size · open-label · IVF not natural conception · cumulative PR mixes IVF and spontaneous
Randomised evidence for improved ovulation with a GLP-1RA regimen.
“GLP-1RA + Met was more effective than CPA/EE + Met in reducing body weight, BMI, and waist, and improving metabolism, and ovulation in overweight women with PCOS”
Panel auditInternal validity: medium · scope of inference: Overweight women with PCOS; GLP-1RA add-on vs anti-androgen add-on, both on metformin.Key limitations: active comparator not placebo · no numeric ovulation estimate · 12-week duration · no pregnancy outcome
Randomised evidence that semaglutide+metformin raises natural pregnancy rate over metformin alone in overweight/obese PCOS women.
“the COM group demonstrated a significantly higher natural pregnancy rate than the MET group (35% vs. 15%, P < 0.05)”
Panel auditInternal validity: medium · scope of inference: Overweight/obese women with PCOS; semaglutide added to metformin vs metformin.Key limitations: open-label · GLP-1 co-administered with metformin · pregnancy window after semaglutide stopped · ovulation rate not separately reported
3 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent positive signal across multiple primary studies including RCTs supports the claim, but small confounded samples and a thin, indirect natural-pregnancy leg keep it short of Likely.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No GLP-1RA monotherapy versus placebo arm. Every human comparison includes metformin, so the GLP-1-specific effect on ovulation and natural pregnancy cannot be separated from metformin or from weight loss. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised trial with a GLP-1RA-alone arm and a placebo arm (with or without a metformin arm), measuring ovulation and natural conception.
Open question: Does a GLP-1 receptor agonist improve ovulation and natural pregnancy in PCOS independent of metformin? Why it is still open: No corpus study uses GLP-1RA monotherapy against placebo; metformin is present in every arm or as the comparator [2],[8],[9],[14],[19].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19